Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas

Lorenzo Falchi, Jahan Rahman, Lauren Melendez, Monifa Douglas, Walter Ramos Amador, Paul Hamlin, Anita Kumar, Daniela Hoehn, Ya-Hui Lin, View ORCID ProfileQi Gao, Mikhail Roshal, Mark D. Ewalt, View ORCID ProfileAhmet Dogan, Benjamin Greenbaum, View ORCID ProfileGilles A. Salles, View ORCID ProfileSantosha A. Vardhana
doi: https://doi.org/10.1101/2024.07.02.24309792
Lorenzo Falchi
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jahan Rahman
3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
4Department of Epidemiology and Biostatistics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Melendez
3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monifa Douglas
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Ramos Amador
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Hamlin
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Kumar
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Hoehn
5Genmab, Princeton, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ya-Hui Lin
3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Gao
6Hematopathology service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qi Gao
Mikhail Roshal
6Hematopathology service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Ewalt
6Hematopathology service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
7Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmet Dogan
6Hematopathology service, Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmet Dogan
Benjamin Greenbaum
4Department of Epidemiology and Biostatistics, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles A. Salles
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gilles A. Salles
Santosha A. Vardhana
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Weill Cornell Medical College, New York, NY, USA
3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Santosha A. Vardhana
  • For correspondence: falchil{at}mskcc.org vardhans{at}mskcc.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Leveraging endogenous tumor-resident T-cells for immunotherapy using bispecific antibodies (BsAb) targeting CD20 and CD3 has emerged as a promising therapeutic strategy for patients with B-cell non-Hodgkin lymphomas. However, features associated with treatment response or resistance are unknown. To this end, we analyzed data from patients treated with epcoritamab-containing regimens in the EPCORE NHL-2 trial (NCT04663347). We observed downregulation of CD20 expression on B-cells following treatment initiation both in progressing patients and in patients achieving durable complete responses (CR), suggesting that CD20 downregulation does not universally predict resistance to BsAb-based therapy. Single-cell immune profiling of tumor biopsies obtained following one cycle of therapy revealed substantial clonal expansion of cytotoxic CD4+ and CD8+ T-cells in patients achieving CR, and an expansion of follicular helper and regulatory CD4+ T-cells in patients whose disease progressed. These results identify distinct tumor-resident T-cell profiles associated with response or resistance to BsAb therapy.

Competing Interest Statement

L.F. Has received research funding from Genmab A/S, AbbVie, Inc., F. Hoffmann-La Roche AG, Genentech Inc., Innate Pharma S.A.; has provided consulting services for Genmab A/S, AbbVie, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Evolveimmune Therapeutics, Inc., Sanofi, S.A.; has served as an advisor for AbbVie, Inc., Seagen, Inc., Ipsen Biopharmaceuticals, Inc., ADC therapeutics S.A.; and has received travel reimbursement from Genmab A/S, AbbVie, Inc. S.A.V. previously served as an advisor for Immunai, has provided consulting services for ADT Therapeutics and Koch Disruptive Technologies, and has received funding from BMS. G.S. has received financial compensation for consulting services in the last 12 months from: Abbvie, Atb Therapeutics, Beigene, BMS, Genentech/Roche, Genmab, Janssen, Innate Pharma, Incyte, Ipsen, Kite/Gilead, Merck, Modex, Molecular Partners, Novartis, Nurix, Orna Therapeutics, and Treeline. He is a shareholder of Owkin. He has received research support from Abbvie, Genentech, Genmab, Janssen, Ipsen, and Nurix, which his institution managed.

Clinical Trial

NCT04663347

Funding Statement

This work was supported by a Steven Greenberg Lymphoma Grant and a Priority Research Grant from the Lymphoma Research Foundation (S.A.V.) as well as MSKCC Core Grant P30 CA008748. We thank Dr. Andrew Steele for his insightful input.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was assigned IRB Protocol #21-164, was approved as per 45 CFR 46.111 and/or 21 CFR 56.111 by the MSKCC Institutional Review Board/Privacy Board-A initially on April 5, 2021 and conducted in accordance with the principles outlined in the Declaration of Helsinki. Approval of the study with amendments was most recently issued on June 7, 2024.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 05, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas
Lorenzo Falchi, Jahan Rahman, Lauren Melendez, Monifa Douglas, Walter Ramos Amador, Paul Hamlin, Anita Kumar, Daniela Hoehn, Ya-Hui Lin, Qi Gao, Mikhail Roshal, Mark D. Ewalt, Ahmet Dogan, Benjamin Greenbaum, Gilles A. Salles, Santosha A. Vardhana
medRxiv 2024.07.02.24309792; doi: https://doi.org/10.1101/2024.07.02.24309792
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas
Lorenzo Falchi, Jahan Rahman, Lauren Melendez, Monifa Douglas, Walter Ramos Amador, Paul Hamlin, Anita Kumar, Daniela Hoehn, Ya-Hui Lin, Qi Gao, Mikhail Roshal, Mark D. Ewalt, Ahmet Dogan, Benjamin Greenbaum, Gilles A. Salles, Santosha A. Vardhana
medRxiv 2024.07.02.24309792; doi: https://doi.org/10.1101/2024.07.02.24309792

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)